Main Menu
Untitled Page
Home > Equity > Company info > Company Snapshot
22 November 2017

Search Quotes

  Enter at least 3 characters from BSE Code for a company or the company's name

Sun Pharmaceuticals Industries Ltd (Pharmaceuticals - Indian - Bulk Drugs & Formln)

Last Price 531.35
Net Changes -6.70
Volume 1087963
Prev Close 538.05
531.35 -6.70 (-1.25%)
Date: Nov 22,2017 10:59:59




Index Details Pharmaceuticals - Indian - Bulk Drugs & Formln


Chart

Stock Price Details

Market Statistics

Open Price 541.95 Div Yield (%) 0.65
Buy (Size) 532.55(×220) Eps(Rs) 0.7
Sell (Size) 532.90(×316) Book Value(Rs) 81.1542749
Buy Quantity 220 Market Cap(Rs.Cr) 129094.77
Sell Quantity 316 Face Value(Rs) 1
Today's High 541.95 Market Lot 1
Today's Low 530.5 AGM Date Sep
52-Week High 730.75 Book Closure Date Sep
52-Week Low 433.15 ISIN No. INE044A01036

Share Holding Pattern

  No Of shares % Share Holding
Total Foreign (Promoter & Group) 0 0.00
Indian (Promoter & Group) 1304855381 54.38
Total of Promoter 1304855381 54.38
Non Promoter (Institution) 768972671 32.05
Non Promoter (Non-Institution) 325478899 13.57
Total Non Promoter 1094451570 45.62
Total Promoter & Non Promoter 2399306951 100.00
Custodians(Against Depository Receipts) 1135 0.00
Grand Total 2399308086 100.00

Company News

15-Nov-2017  Sun Pharma drops after reporting weak Q2 results
Sun Pharma drops after reporting weak Q2 results

The result was announced after market hours yesterday, 14 November 2017. The stock had dropped 1.19% to Rs 526.15 ahead of Q2 results yesterday, 14 November 2017.

Meanwhile, the S&P BSE Sensex was down 41.73 points, or 0.13% to 32,900.14.

On the BSE, 2.27 lakh shares were traded in the counter so far, compared with average daily volumes of 4.83 lakh shares in the past one quarter. The stock had hit a high of Rs 520.50 and a low of Rs 510.30 so far during the day. The stock had hit a 52-week high of Rs 730.75 on 2 December 2016. The stock had hit a 52-week low of Rs 433.15 on 14 August 2017.

The stock had underperformed the market over the past one month till 14 November 2017, falling 1.6% compared with 1.57% rise in the Sensex. The scrip had, however, outperformed the market in the past one quarter, gaining 11.35% as against Sensex's 4.75% rise. The scrip had, however, underperformed the market in the past one year, falling 23.63% as against Sensex's 22.83% rise.

The large-cap company has equity capital of Rs 239.93 crore. Face value per share is Re 1.

Sales and net profit of Q2 September 2017 are not comparable with relevant periods of last year due to US sales for Q2 last year includes the benefit of the 180-day exclusivity for Imatinib which expired in July-2016. Also, post the implementation of Goods and Service Tax (GST) with effect from 1 July 2017, India sales are now reported net of GST while sales in Q2 included excise duty which is now subsumed in GST.

Dilip Shanghvi, Managing Director of the company said that a challenging US generic pricing environment coupled with continued investments in building global specialty business has impacted Q2 performance. The company expects performance to gradually improve in the second half of this year, he added.

Sun Pharmaceutical Industries is a specialty generic pharmaceutical company and India's top pharmaceutical company.

15-Nov-2017  Other announcement of Sun Pharmaceutical Industrie
Other announcement of Sun Pharmaceutical Industrie

Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding Scheme of Arrangement approved at Board Meeting held on November 14, 2017
15-Nov-2017  Sun Pharmaceutical Industries Limited - Outcome of Board Meeting
Sun Pharmaceutical Industries Limited - Outcome of Board Meeting

Sun Pharmaceutical Industries Limited has informed the Exchange regarding Outcome of Board Meeting held on November 14, 2017.
15-Nov-2017  Sun Pharmaceutical Industries Limited - Press Release
Sun Pharmaceutical Industries Limited - Press Release

Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated November 14, 2017, titled 'Sun Pharma reports Q2FY18 results, Q2 Gross Sales at Rs. 6,590 crores, Q2 Net Profit at Rs. 912 crores
15-Nov-2017  Sun Pharmaceutical Industries Limited - Scheme of Arrangement
Sun Pharmaceutical Industries Limited - Scheme of Arrangement

Sun Pharmaceutical Industries Limited has informed the Exchange regarding Scheme of Arrangement approved at Board Meeting held on November 14, 2017.
14-Nov-2017  Sun Pharmaceuticals Industries consolidated net profit decline...
Sun Pharmaceuticals Industries consolidated net profit declines 59.46% in the September 2017 quarter

Net profit of Sun Pharmaceuticals Industries declined 59.46% to Rs 1001.79 crore in the quarter ended September 2017 as against Rs 2471.11 crore during the previous quarter ended September 2016. Sales declined 14.96% to Rs 6590.06 crore in the quarter ended September 2017 as against Rs 7749.15 crore during the previous quarter ended September 2016.

ParticularsQuarter Ended
 Sep. 2017Sep. 2016% Var.
Sales6590.067749.15 -15
OPM %20.8740.88 -
PBDT1473.013233.37 -54
PBT1114.362929.54 -62
NP1001.792471.11 -59
14-Nov-2017  Sun Pharmaceuticals Industries standalone net profit rises 207...
Sun Pharmaceuticals Industries standalone net profit rises 207.84% in the September 2017 quarter

Net profit of Sun Pharmaceuticals Industries rose 207.84% to Rs 577.05 crore in the quarter ended September 2017 as against Rs 187.45 crore during the previous quarter ended September 2016. Sales declined 9.99% to Rs 1769.86 crore in the quarter ended September 2017 as against Rs 1966.37 crore during the previous quarter ended September 2016.

ParticularsQuarter Ended
 Sep. 2017Sep. 2016% Var.
Sales1769.861966.37 -10
OPM %-4.720.40 -
PBDT678.71294.74 130
PBT573.63190.57 201
NP577.05187.45 208
14-Nov-2017  Other announcement of Sun Pharmaceutical Industrie
Other announcement of Sun Pharmaceutical Industrie

This is to inform you that the Committee of Directors (Allotment) at its meeting held today i.e. on Tuesday, November 14, 2017 allotted 1,260 (One Thousand Two Hundred and Sixty) equity shares of the Company of Re 1/- each, on exercise of stock options under the SUN Employee Stock Option Scheme -2015. Accordingly, post the above allotment the paid-up equity share capital of the Company is Rs. 2,39,93,09,346/- (Rupees Two Hundred and Thirty Nine Crores Ninety Three Lakhs Nine Thousand Three Hundred and Forty Six Only) divided into Rs. 2,39,93,09,346 (Two Hundred and Thirty Nine Crores Ninety Three Lakhs Nine Thousand Three Hundred and Forty Six Only) equity shares of Re.1/- each.
14-Nov-2017  Sun Pharmaceutical Industries Limited - Outcome of Board Meeting
Sun Pharmaceutical Industries Limited - Outcome of Board Meeting

Sun Pharmaceutical Industries Limited has informed the Exchange regarding Outcome of Board Meeting held on November 14, 2017.
01-Nov-2017  Sun Pharmaceutical Industries Limited - Press Release
Sun Pharmaceutical Industries Limited - Press Release

Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated October 31, 2017, titled 'Sun Pharma to announce second quarter results on November 14, 2017'.
Incorporation Year 1993 
Registered Office Sun Pharma Advanced Res.Centre,Tandalja,
Vadodara,
Gujarat-390020
Telephone 91-265-6615500 
Fax 91-265-2354897 
Chairman Israel Makov
Managing Director Dilip S Shanghvi
Company Secretary Sunil R Ajmera 
Auditor Deloitte Haskins & Sells/S R B C & Co LLP 
Face Value(Rs)
Market Lot
Listing MCX-SX,BSE,NSE 
Registrar Link Intime India Pvt Ltd
C-101 247 Park,L B S Marg,Vikhroli West,Mumbai-400083 
Toll Free number: 1800-425-5501 / 1800-103-5501
FINANCIAL TOOLS